More about post-transplant cyclophosphamide in haploidentical grafts: full or reduced doses?
ABSTRACTHaploidentical hematopoietic can be conducted on an outpatient basis but the two main reasons to accept into the hospital a patient in this setting are complications of the hematological toxicity and/or the cytokine-release syndrome. With the aim of reducing the post-transplant cyclophospham...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Hematology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2024.2313357 |
| _version_ | 1797319310837809152 |
|---|---|
| author | Moisés Manuel Gallardo-Pérez César Homero Gutiérrez-Aguirre Juan Carlos Olivares-Gazca Guillermo José Ruiz-Argüelles |
| author_facet | Moisés Manuel Gallardo-Pérez César Homero Gutiérrez-Aguirre Juan Carlos Olivares-Gazca Guillermo José Ruiz-Argüelles |
| author_sort | Moisés Manuel Gallardo-Pérez |
| collection | DOAJ |
| description | ABSTRACTHaploidentical hematopoietic can be conducted on an outpatient basis but the two main reasons to accept into the hospital a patient in this setting are complications of the hematological toxicity and/or the cytokine-release syndrome. With the aim of reducing the post-transplant cyclophosphamide-dependent toxicity without compromising its effectivity, attempts to reduce the dose of post-transplant cyclophosphamide have been made: Decreases from the conventional total dose of post-transplant cyclophosphamide (100 mg/Kg) have been explored worldwide, showing that decreasing the total dose to even 50 mg/Kg significantly decreases the toxicity of the procedure without compromising its efficacy, safety and results. We present here the salient data of the attempts to diminish the doses of post-transplant cyclophosphamide which have been done and published worldwide, information that suggests that the conventional doses of post-transplant cyclophosphamide can be significantly reduced thus decreasing the toxicity, without compromising the effectiveness of the procedure, mainly the development of graft versus host disease. |
| first_indexed | 2024-03-08T04:04:06Z |
| format | Article |
| id | doaj.art-d7ab91357a1948cc9ac543b4f56bc62f |
| institution | Directory Open Access Journal |
| issn | 1607-8454 |
| language | English |
| last_indexed | 2024-03-08T04:04:06Z |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Hematology |
| spelling | doaj.art-d7ab91357a1948cc9ac543b4f56bc62f2024-02-09T07:59:17ZengTaylor & Francis GroupHematology1607-84542024-12-0129110.1080/16078454.2024.2313357More about post-transplant cyclophosphamide in haploidentical grafts: full or reduced doses?Moisés Manuel Gallardo-Pérez0César Homero Gutiérrez-Aguirre1Juan Carlos Olivares-Gazca2Guillermo José Ruiz-Argüelles3Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, MéxicoHospital Universitario “Dr. José Eleuterio González” de la Universidad Autónoma de Nuevo León, Monterrey, MéxicoCentro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, MéxicoCentro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, MéxicoABSTRACTHaploidentical hematopoietic can be conducted on an outpatient basis but the two main reasons to accept into the hospital a patient in this setting are complications of the hematological toxicity and/or the cytokine-release syndrome. With the aim of reducing the post-transplant cyclophosphamide-dependent toxicity without compromising its effectivity, attempts to reduce the dose of post-transplant cyclophosphamide have been made: Decreases from the conventional total dose of post-transplant cyclophosphamide (100 mg/Kg) have been explored worldwide, showing that decreasing the total dose to even 50 mg/Kg significantly decreases the toxicity of the procedure without compromising its efficacy, safety and results. We present here the salient data of the attempts to diminish the doses of post-transplant cyclophosphamide which have been done and published worldwide, information that suggests that the conventional doses of post-transplant cyclophosphamide can be significantly reduced thus decreasing the toxicity, without compromising the effectiveness of the procedure, mainly the development of graft versus host disease.https://www.tandfonline.com/doi/10.1080/16078454.2024.2313357Allogeneic hematopoietic stem cell transplantationpost-transplantation cyclophosphamidegraft-versus-host diseaseoutpatientcytokine release syndromeallograft |
| spellingShingle | Moisés Manuel Gallardo-Pérez César Homero Gutiérrez-Aguirre Juan Carlos Olivares-Gazca Guillermo José Ruiz-Argüelles More about post-transplant cyclophosphamide in haploidentical grafts: full or reduced doses? Hematology Allogeneic hematopoietic stem cell transplantation post-transplantation cyclophosphamide graft-versus-host disease outpatient cytokine release syndrome allograft |
| title | More about post-transplant cyclophosphamide in haploidentical grafts: full or reduced doses? |
| title_full | More about post-transplant cyclophosphamide in haploidentical grafts: full or reduced doses? |
| title_fullStr | More about post-transplant cyclophosphamide in haploidentical grafts: full or reduced doses? |
| title_full_unstemmed | More about post-transplant cyclophosphamide in haploidentical grafts: full or reduced doses? |
| title_short | More about post-transplant cyclophosphamide in haploidentical grafts: full or reduced doses? |
| title_sort | more about post transplant cyclophosphamide in haploidentical grafts full or reduced doses |
| topic | Allogeneic hematopoietic stem cell transplantation post-transplantation cyclophosphamide graft-versus-host disease outpatient cytokine release syndrome allograft |
| url | https://www.tandfonline.com/doi/10.1080/16078454.2024.2313357 |
| work_keys_str_mv | AT moisesmanuelgallardoperez moreaboutposttransplantcyclophosphamideinhaploidenticalgraftsfullorreduceddoses AT cesarhomerogutierrezaguirre moreaboutposttransplantcyclophosphamideinhaploidenticalgraftsfullorreduceddoses AT juancarlosolivaresgazca moreaboutposttransplantcyclophosphamideinhaploidenticalgraftsfullorreduceddoses AT guillermojoseruizarguelles moreaboutposttransplantcyclophosphamideinhaploidenticalgraftsfullorreduceddoses |